Inflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.

The EU Commission’s Chief Scientific Advisors urge the Commission to revise the EU’s GMO Directive in order to harness gene editing.

The flexible BioFlo 120 bioreactor/fermentor control station is capable of microbial fermentation as well as mammalian cell culture applications. 

Boehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.

Researchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.

Hox Therapeutics has announced the appointment of Dr Karl Keegan as Chief Executive Officer.

AstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum AB.  

Swiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing.

Antimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report. 

A new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA).